top of page

Biopharma Daily Stock Updates - 07/09/21

$XBI $133.8 +1.4%

 

COVID Updates

$HGEN +2.2% UK’s MHRA accepts Humanigen’s submission of Lenzilumab for Marketing Authorization in COVID-19 for expedited rolling review. source



Pipeline Updates

$IMAB +7.7% I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology Platforms. source


$MDWD +5.8% MediWound Announces Peer-Reviewed Paper Detailing EscharEx Phase 2 Randomized Control Trial Results Published in the Online Wound Repair and Regeneration Journal. source


$GALT +25.0% Galectin Therapeutics Announces Positive Top-Line Results from a Phase 1b Clinical Trial Extension of Belapectin in Combination with KEYTRUDA® in Advanced Metastatic Melanoma and Head and Neck Cancer. source


$AMTI +2.3% Applied Molecular Transport Presents Additional Positive Data from Oral AMT-101 Phase 1b in Ulcerative Colitis at ECCO ‘21 Virtual Congress. source


$MTEM +1.2% Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors. source


$SGTX -25.3% Sigilon Therapeutics Announces Clinical Hold on SIG-001 Phase 1/2 Study in Hemophilia A. source


$BLUE +0.5% bluebird bio Announces Positive Recommendation by PRAC Regarding Article 20 Safety Referral Review of ZYNTEGLO™ Gene Therapy for Transfusion-Dependent β-thalassemia and Marketing to Resume in EU. source


$MORF +6.4% Morphic Reports New Data from Positive Phase 1 Study of MORF-057, Oral Integrin Inhibitor Candidate for IBD. source



Financial Updates

$RPHM -2.5% Reneo Pharmaceuticals Announces Partial Waiver of Lock-Up Restriction. source


$IMPL +13.5% On 7/7 Impel NeuroPharma Enters Into a $50 Million Debt Financing Agreement With Oxford Finance LLC and Silicon Valley Bank. source


$LMNL +4.9% Liminal BioSciences Announces Closing of Sale of Plasma-Derived Therapeutics Manufacturing Facility source

 

Posted by FS

0 comments

Kommentare


bottom of page